---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-331522"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2026-08-04T11:09:08+00:00"
generated_at: "2026-08-04T11:10:10.114472+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics Q2 net loss $122.7M; first patient dosed in BEAM-302 pivotal trial

## Summary
- Net loss of $122.7M ($1.18 per share) vs $102.1M loss in Q2 2025; R&D expenses $95.1M.
- First patient dosed in global pivotal cohort of BEAM-302 for AATD; updated data at ERS Congress Sept 2026.
- Dosing complete for all patients in BEACON trial of risto-cel for SCD; BLA submission expected as early as year-end 2026.
- FDA cleared IND for BEAM-304 in PKU; clinical start-up activities underway.
- Cash $1.2B as of June 30, 2026; with $200M from Sixth Street, runway into mid-2029.

## SEC filing metadata
- accession: 0001193125-26-331522
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2026-08-04T11:09:08+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/0001193125-26-331522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-331522
- JSON: https://secwatch.observer/filing/0001193125-26-331522.json
- Plain text: https://secwatch.observer/filing/0001193125-26-331522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.